Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Hanmi Out-licenses pan-RAF Inhibitor to Genentech for $920 Million

publication date: Sep 29, 2016

South Korea's Hanmi Pharma has announced another major out-licensing: the company sold global rights (ex-Korea) for its pan-RAF inhibitor, HM95573, to Genentech, a unit of Roche, in an $910 million deal. Hanmi will receive $80 million upfront and double digit royalties on sales of certain products covered by the agreement. Further details were not provided. Hanmi has been spectacularly successful in finding partners for its portfolio of innovative drug candidates. During 2015-16, it has signed almost $7 billion of out-licensing deals. More details .....

Stock Symbols: (KRX:128940) (SIX: ROG)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital